Evaluation of 64Cu-ATSM PET/CT as a predictor of response to neoadjuvant therapy in locally advanced rectal cancer (TEP-64Cu-ATSM-Rectum)
TEP-64Cu-ATSM-Rectum
Phase 2 other active
Quick answer
Evaluation of 64Cu-ATSM PET/CT as a predictor of response to neoadjuvant therapy in locally advanced rectal cancer (TEP-64Cu-ATSM-Rectum) for Rectal adenocarcinoma is a Phase 2 program (other) at CERO THERAPEUTICS HOLDINGS, INC. with 1 ClinicalTrials.gov record(s).
Program details
- Company
- CERO THERAPEUTICS HOLDINGS, INC.
- Indication
- Rectal adenocarcinoma
- Phase
- Phase 2
- Modality
- other
- Status
- active